chenodeoxycholic acid has been researched along with Diabetes Mellitus, Type 1 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Salami, H; Chester, J; Danic, M; Dass, C; Ionescu, CM; Johnston, E; Jones, M; Kovacevic, B; Mikov, M; Mooranian, A; Wagle, SR; Walker, D | 1 |
| Al-Salami, H; Goločorbin-Kon, S; Ionescu, CM; Kovačević, B; Luna, G; Mikov, M; Mooranian, A; Takechi, R; Zamani, N | 1 |
| Al-Salami, H; Arfuso, F; Chen-Tan, N; Mathavan, S | 1 |
| Al-Salami, H; Butt, G; Golocorbin-Kon, S; Mikov, M; Tucker, I | 1 |
4 other study(ies) available for chenodeoxycholic acid and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Chenodeoxycholic Acid Pharmacology in Biotechnology and Transplantable Pharmaceutical Applications for Tissue Delivery: An Acute Preclinical Study.
Topics: Animals; Biotechnology; Capsules; Chenodeoxycholic Acid; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Gastrointestinal Agents; Insulin-Secreting Cells; Islets of Langerhans Transplantation; Male; Mice; Mice, Inbred BALB C | 2021 |
Oral gavage of nano-encapsulated conjugated acrylic acid-bile acid formulation in type 1 diabetes altered pharmacological profile of bile acids, and improved glycaemia and suppressed inflammation.
Topics: Acrylates; Animals; Bile Acids and Salts; Blood Glucose; Chenodeoxycholic Acid; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Feces; Insulin; Lithocholic Acid; Mice; Nanoconjugates; Ursodeoxycholic Acid | 2020 |
The role of the bile acid chenodeoxycholic acid in the targeted oral delivery of the anti-diabetic drug gliclazide, and its applications in type 1 diabetes.
Topics: Administration, Oral; Alginates; Capsules; Chenodeoxycholic Acid; Diabetes Mellitus, Type 1; Drug Compounding; Gliclazide; Glucuronic Acid; Hexuronic Acids; Humans; Hypoglycemic Agents | 2016 |
Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats.
Topics: Administration, Oral; Animals; Biological Availability; Blood Glucose; Chenodeoxycholic Acid; Cholic Acids; Chromatography, High Pressure Liquid; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Food-Drug Interactions; Gliclazide; Hypoglycemic Agents; Injections, Intravenous; Male; Probiotics; Random Allocation; Rats; Rats, Wistar | 2012 |